CSIMarket Company Name, Ticker, Suppliers, else..


Protagonist Therapeutics inc   (NASDAQ: PTGX)
Other Ticker:  
 


 

Protagonist Therapeutics inc

PTGX's Financial Statements and Analysis



Protagonist Therapeutics inc narrowed third quarter of 2024 net loss per share of $-0.54 compare to net loss per share of $-0.58 recorded in the same quarter a year ago a decrease compare to $-0.50 realized in previous quarter.


third quarter of 2024
Earnings Per Share Revenues
$ -0.54 $  5 Mill
$+0.04     $+5M    



Protagonist Therapeutics Inc 's Revenue rose by 0 % in third quarter of 2024 (Sep 30 2024) year on year, to $5 million and advanced by 12.19 % sequentially.


Protagonist Therapeutics Inc is

More on PTGX's Income Statement



Protagonist Therapeutics Inc in the third quarter of 2024 recorded net loss of $-33.210 million, an improvement compare to net loss of $-34.105 million in III. Quarter a year ago.

Sequentially net loss advanced

More on PTGX's Growth

Protagonist Therapeutics Inc Inventories
In Sep 30 2024 company's net cash and cash equivalents decreased by $-225 million, capital expenditures fell by -0.40491.83%, to $-1 millions compare to same quarter a year ago

More on PTGX's Cash flow Statement


Protagonist Therapeutics inc does not pay out common stock dividend.

In trailing twelve-month period Protagonist Therapeutics inc earned $ 3.73 cash per share, on a free-cash flow basis 142.85 % of net earning per share.

Book value fell by -2.47 % sequentially to $8.61 per share.
Tangible Book value fell to $ 8.61 per share from $ 8.83.

Company issued 0.46 million shares or 0.75 % in Sep 30 2024.


• More on PTGX's Dividends

 Market Capitalization (Millions) 2,278
 Shares Outstanding (Millions) 62
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 324
 Net Income (TTM) (Millions $) 171
 Cash Flow (TTM) (Millions $) -99
 Capital Exp. (TTM) (Millions $) -1
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 103




Protagonist Therapeutics inc does not pay out common stock dividend.

In trailing twelve-month period Protagonist Therapeutics inc had $ 3.73 cash flow per share, on a free-cash flow basis 142.85 % of net earning per share.

Book value fell by -2.47 % sequentially to $8.61 per share.
Tangible Book value fell to $ 8.61 per share from $ 8.83.

Company issued 0.46 million shares or 0.75 % in Sep 30 2024.


• More on PTGX's Balance Sheets

 Market Capitalization (Millions) 2,278
 Shares Outstanding (Millions) 62
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 324
 Net Income (TTM) (Millions $) 171
 Cash Flow (TTM) (Millions $) -99
 Capital Exp. (TTM) (Millions $) -1
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 103
   


  News about Protagonist Therapeutics inc Earnings

2. Protagonist Therapeutics Inc Reports Impressive Revenue Growth in First Quarter of 2024 Financial Results

Protagonist Therapeutics Inc, a biopharmaceutical company specializing in the development of peptide-based therapies, has reported impressive financial results for the first quarter of 2024. With revenues reaching $254.953 million, the company has achieved substantial growth compared to the same period last year. Moreover, the net earnings for the first quarter of 2024 amounted to $207.340 million, marking a significant improvement from a net loss of $33.725 million in the previous year.
One of the highlights of Protagonist Therapeutics' financial performance is the improvement in its profit margins. The net margin for the first quarter of 2024 rose to an impressive 81.32%, indicating the company's abili...

Protagonist Therapeutics Inc. Reports Impressive Revenue of $60 Million in Q4 2023

Protagonist Therapeutics Inc. (PTGX) has showcased strong performance in recent trading days, with a solid gain of 8.45%. This surge in stock price has brought the share value to 26.09% during the first quarter of 2024. PTGX stock is currently on an upward trajectory and is only 1.9% away from its 52-week high of $30.1.
One of the main contributing factors to PTGX's success is its impressive financial results. As revealed by the company, in the fiscal time-frame of October to December 31, 2023, Protagonist Therapeutics Inc. achieved a remarkable revenue of $60 million. This represents a significant improvement compared to the same quarter the previous year when the company experienced a net loss of -$34....

Protagonist Therapeutics Inc. Reports Significant Operating Deficit of $-38.326 Million in Q3 2023



The Major Pharmaceutical Preparations sector has been dominated by industry leaders, while some lesser-known companies have remained somewhat overlooked. Among them is Protagonist Therapeutics Inc (PTGX), an evolving entity that recently disclosed its third-quarter financial results for 2023. Despite trailing behind the sector leaders, these results offer valuable insights into the company's current performance and its potential impact on the company's future trajectory.
Operating Deficit Trends:
In the third quarter of 2023, PTGX reported an operating deficit of $-38.326 million. To put this figure into context, it's important to analyze the company's performance in the same period of the ...

Protagonist Therapeutics Reports Loss of $-0.68 Per Share in Q2 2023, But Shows Signs of Recovery

Protagonist Therapeutics Inc (PTGX) has recently released its financial results for the April to June 30, 2023 fiscal span, and while the numbers may not be impressive at first glance, there are underlying factors that suggest a potential turnaround for the company. Despite a loss per share of $-0.68, an improvement from $-0.84 compared to the previous year, and an increased shortfall from the prior financial reporting period, there are reasons to remain bullish about PTGX.
One notable aspect of the financial report is the consistent revenue of $0.00 million, which remained unchanged from the previous year. While this may seem discouraging, it is essential to note that there has been no significant drop,...

Protagonist Therapeutics Inc Reports Larger Loss in Fiscal Year Ending March 2023

Protagonist Therapeutics Inc is a biopharmaceutical company that specializes in developing peptide-based drugs to treat various diseases. The company's objective is to leverage its proprietary technology platform to create novel and targeted therapeutics that can improve outcomes for patients suffering from a wide range of medical conditions, including gastrointestinal-related issues, autoimmune disorders, and certain types of cancer.
Unfortunately, the company's financial performance for the fiscal year ending March 31, 2023, did not meet expectations. The company's diminishing returns grew to $-0.67 per share, compared to $-0.43 per share the previous year. However, the EPS improved from $-0.69 per sha...


Date modified: 2024-11-10T07:18:13+00:00





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com